Click here for free access to our latest coronavirus/COVID-19 research, commentary, and news.

Support nonprofit science journalism

Science’s extensive COVID-19 coverage is free to all readers. To support our nonprofit science journalism, please make a tax-deductible gift today.

Webinar Technology

Deciphering immuno-oncology: Targeting cellular mechanisms of the tumor immune response

This webinar is brought to you by the Science/AAAS Custom Publishing Office

Deciphering immuno-oncology: Targeting cellular mechanisms of the tumor immune response

26 February 2020

12:00 p.m. ET

Register to watch recording

Speakers

Tumors are complex hubs of cellular activity that incorporate immune cells, vasculature, and even bacteria. It has become increasingly clear that a better understanding of this tumor microenvironment and the different types of immune cells within it is critical to developing more effective cancer therapies. In particular, immunotherapies that target the signaling mechanisms of T cells have shown great promise for many patients. However, these techniques have proven successful for only a fraction of people and against just a few cancer types. A detailed dissection of the molecular signaling switches that control immune cell activation and tumor checkpoint evasion is required if we hope to broaden the reach of immunotherapy treatments. Our speakers will describe key signaling mechanisms and shed light on how they can be utilized to better activate and control immune cells in the tumor microenvironment.

During the webinar, viewers will:

  • Discover how they can effectively target key signaling molecules and immune markers
  • Learn about new discoveries demonstrating the impact of stromal cells on immune checkpoint blockades
  • Be introduced to the complex signaling interactions between oncogenes, immune cells, and the tumor microenvironment
  • Gain insight into how therapeutics can target signaling pathways to better activate an immune response
  • Have the opportunity to ask questions during the live broadcast.

This webinar will last for approximately 60 minutes.

Speaker bios

Matthew Galsky, M.D.

Icahn School of Medicine at Mount Sinai
New York, NY

Dr. Galsky is a medical oncologist with a clinical and research focus on bladder cancer. He completed his oncology training at Memorial Sloan Kettering Cancer Center and subsequently joined the faculty. In 2010, he was recruited to the Mount Sinai School of Medicine/Tisch Cancer Institute, where he currently serves as professor of medicine, director of Genitourinary Medical Oncology, and codirector of the Center of Excellence for Bladder Cancer. His research efforts involve team science–based approaches focused on dissecting the mechanistic underpinnings of response and resistance to immunotherapeutic strategies in bladder cancer. 

Elizabeth M. Jaffee, M.D.

Johns Hopkins University
Baltimore, MD

Dr. Jaffee is an internationally recognized expert in cancer immunology and pancreatic cancer. She is deputy director of the Sidney Kimmel Comprehensive Cancer Center, codirector of the Skip Viragh Center for Pancreatic Cancer, and associate director of the Bloomberg~Kimmel Institute for Cancer Immunotherapy, all at Johns Hopkins University. Her research focus is on developing novel immunotherapies for the treatment and prevention of pancreatic cancer. She is a past president of the American Association for Cancer Research (AACR) and has served on a number of committees at the National Cancer Institute, including cochair of the Blue Ribbon Panel that provided scientific advice to former Vice President Biden’s Moonshot Initiative. She currently serves as chair of the National Cancer Advisory Board and chief medical advisor to the Lustgarten Foundation for Pancreatic Cancer Research. She is inaugural director of the new Convergence Institute at Johns Hopkins and was recently elected to the National Academy of Medicine, as well as being a Fellow of the American College of Physicians.

Sean Sanders, Ph.D.

Science/AAAS
Washington, DC

Dr. Sanders did his undergraduate training at the University of Cape Town, South Africa, and his Ph.D. at the University of Cambridge, UK, supported by the Wellcome Trust. Following postdoctoral training at the National Institutes of Health and Georgetown University, Dr. Sanders joined TranXenoGen, a startup biotechnology company in Massachusetts working on avian transgenics. Pursuing his parallel passion for writing and editing, Dr. Sanders joined BioTechniques as an editor, before joining Science/AAAS in 2006. Currently, Dr. Sanders is the Director and Senior Editor for Custom Publishing for the journal Science and Program Director for Outreach.

Sponsored by

Get webinar alerts

For more information on upcoming webinars, recorded sessions and more, sign up for webinar alerts.

Sign up here